To read the full story, subscribe or sign in.

Frequency locks on $32M series A for hearing loss drug

April 12, 2017

Frequency Therapeutics Inc., a company working to develop a progenitor cell-activating hearing restoration therapy, has closed a $32 million series A financing led by Cobro Ventures.

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Dec. 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 23, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...